{"company":{"id":3781747,"name":"Corteria","domain":"corteriapharma.com","url":"https://alion.io/company/corteriapharma"},"section":"news","answer":"Corteria: 9 headlines on record, 1 headline in the last 90 days. Its story counts 2 milestones.","figures":[{"label":"Headlines","value":"9"},{"label":"In 90 days","value":"1"},{"label":"Milestones","value":"2"}],"blocks":[{"key":"news","title":"Headlines","source":"the outlets named on each headline, each story once","rows":9},{"key":"story","title":"Milestones","source":"Each milestone is dated by its source: registers, filings, the press","rows":2}],"news":[{"date":"2026-09-16","kind":"Blog","title":"Corteria abstract was selected for oral presentation at EASD 2026 of preclinical data of COR-1389, first-in-class and best-in-class CRF2 agonist!","url":"https://corteriapharma.com/news/corteria-abstract-was-selected-for-oral-presentation-at-easd-2026-of-preclinical-data-of-cor-1389-first-in-class-and-best-in-class-crf2-agonist/"},{"date":"2025-07-25","kind":"News","title":"En bref : Corteria Pharmaceuticals, Nemera","source":"usinenouvelle.com","url":"https://usinenouvelle.com/article/en-bref-corteria-pharmaceuticals-nemera.N2235752"},{"date":"2025-07-21","kind":"Blog","title":"Corteria announces significant progresses with the two first-in-class CRF2 agonists","url":"https://corteriapharma.com/news/corteria-announces-significant-progresses-with-the-two-first-in-class-crf2-agonists/"},{"date":"2025-07-21","kind":"News","title":"Corteria Pharmaceuticals initiates Phase 2 trial in heart failure and Phase 1 trial in obesity with its first-in-class CRF2 agonists","source":"menafn.com","url":"https://menafn.com/1109825972/Corteria-Pharmaceuticals-initiates-Phase-2-trial-in-heart-failure-and-Phase-1-trial-in-obesity-with-its-first-in-class-CRF2-agonists"},{"date":"2024-06-28","kind":"Blog","title":"ESC Heart Failure 2024","url":"https://corteriapharma.com/news/esc-heart-failure-2024/"},{"date":"2024-03-27","kind":"News","title":"Corteria Pharmaceuticals announces initiation of Phase 1 study to evaluate CRF2 agonist COR-1167 for treatment of worsening heart failure","source":"menafn.com","url":"https://menafn.com/1108027271/Corteria-Pharmaceuticals-announces-initiation-of-Phase-1-study-to-evaluate-CRF2-agonist-COR-1167-for-treatment-of-worsening-heart-failure"},{"date":"2024-03-26","kind":"Blog","title":"Corteria annonces the First-in-Human study of COR-1167","url":"https://corteriapharma.com/news/corteria-annonces-the-first-in-human-study-of-cor-1167/"},{"date":"2024-01-08","kind":"Blog","title":"Corteria Pharmaceuticals appoints Mark Pruzanski as Chairman of its Board of Directors","url":"https://corteriapharma.com/news/mark-pruzanski-appointment/"},{"date":"2023-09-06","kind":"News","title":"Corteria closes $70.7M series A to advance heart failure candidates","source":"bioworld.com","url":"https://bioworld.com/articles/700810-corteria-closes-707m-series-a-to-advance-heart-failure-candidates?v=preview"}],"story":[{"title":"Raised a round Series A $70.7M · led by OrbiMed","url":"https://bioworld.com/articles/700810-corteria-closes-707m-series-a-to-advance-heart-failure-candidates?v=preview"},{"title":"Founded"}],"as_of":"2026-11-17","cite":"Corteria, News. Alion, Nov 17, 2026. https://alion.io/company/corteriapharma/news","html_url":"https://alion.io/company/corteriapharma/news","json_url":"https://alion.io/company/corteriapharma/news.json","license":"CC BY-SA 4.0","meta":{"source":"Alion","generated_at":"2026-11-17T21:47:21Z"}}